Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380074 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TDP1MAPK1ACHE | |
| SCHEMBL1590024 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TDP1MAPK1ACHE | |
| SCHEMBL68013 | 0.82 | TRPA1 (0.53) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL29457565 | 0.82 | TRPA1 (0.53) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL5872088 | 0.81 | ALOX15 (0.39) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL28562792 | 0.81 | KDM4E (0.46) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL6062069 | 0.81 | ALDH1A1 (0.41) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL12865508 | 0.81 | ALOX15 (0.39) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL2602667 | 0.77 | ESR1 (0.36) | TRPA1ALOX15ATMKDM4EALDH1A1 | |
| SCHEMBL3172727 | 0.77 | ALDH1A1 (0.38) | TRPA1ALOX15ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| WO-2025007401-A1 | CONSTRUCT FOR REAL-TIME TRACING OF SPATIAL GENOME CONFORMATION AND TRANSCRIPTION PRODUCTS IN LIVING CELLS AND USE THEREOF | 生物岛实验室 | 2025-01-09 | — | — | WO | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2022216945-A1 | MACROCYCLIC MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114702411-A | Method for producing 1, 2-benzenedimethanol compound | 高文作物保护公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-108602765-B | Method for producing 1, 2-benzenedimethanol compound | 高文有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-11274076-B2 | Process for preparing 1, 2-benzenedimethanol compound | GOWAN COMPANY, L.L.C. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3415496-B1 | PROCESS FOR PREPARING 1,2-BENZENEDIMETHANOL COMPOUND | GOWAN COMPANY L L C (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200399263-A1 | PROCESS FOR PREPARING 1, 2-BENZENEDIMETHANOL COMPOUND | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2020-12-24 | — | — | US | disclosed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| CN-1468275-A | Preparation of high intrinsic viscosity poly(arylene ether) resins | 通用电气公司 | 2004-01-14 | — | — | CN | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| EP-0600084-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598750-A1 | INDOLES | Pfizer Limited (GB) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993003012-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-02-18 | — | — | WO | disclosed |
| WO-1993002050-A1 | INDOLES | PFIZER LIMITED (GB) | 1993-02-04 | — | — | WO | disclosed |
| EP-0322926-A2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | LONDON DIAGNOSTICS, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399263-A1 | PROCESS FOR PREPARING 1, 2-BENZENEDIMETHANOL COMPOUND | ADH1A, ADH1C, CYP2E1 | TRPA1 970/4885ALOX15 1209/4885ATM 2171/4885 |
| US-11274076-B2 | Process for preparing 1, 2-benzenedimethanol compound | ADH1A, ADH1C, CYP2E1 | TRPA1 970/4885ALOX15 1209/4885ATM 2171/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | TRPA1 1197/4885ALOX15 3471/4885ATM 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.